Improved ELISA for the detection of HBsAg

Isolation and Characterization of Targeting-HBsAg VNAR Single Domain Antibodies from Whitespotted Bamboo Sharks (Chiloscyllium plagiosum)

Immunoglobulin new antigen receptor (IgNAR) is a naturally occurring antibody that consists of only two heavy chains with two independent variable domains. The variable binding domain of IgNAR, called variable new antigen receptor (VNAR), is attractive due to its solubility, thermal stability, and small size. Hepatitis B surface antigen (HBsAg) is a viral capsid protein found on the surface of the Hepatitis B virus (HBV). It appears in the blood of an individual infected with HBV and is widely used as a diagnostic marker for HBV infection. In this study, the whitespotted bamboo sharks (Chiloscyllium plagiosum) were immunized with the recombinant HBsAg protein. Peripheral blood leukocytes (PBLs) of immunized bamboo sharks were further isolated and used to construct a VNAR-targeted HBsAg phage display library. The 20 specific VNARs against HBsAg were then isolated by bio-panning and phage ELISA. The 50% of maximal effect (EC₅₀) of three nanobodies, including HB14, HB17, and HB18, were 4.864 nM, 4.260 nM, and 8.979 nM, respectively. The Sandwich ELISA assay further showed that these three nanobodies interacted with different epitopes of HBsAg protein. When taken together, our results provide a new possibility for the application of VNAR in HBV diagnosis and also demonstrate the feasibility of using VNAR for medical testing.

False decrease of HBsAg S/CO values in serum with high-concentration rheumatoid factors

OBJECTIVES

To investigate whether high-concentration RFs cause false decrease of S/CO values of serum HBsAg.

DESIGN AND METHODS

Serum HBsAg was determined in 100 RF-positive sera using one-step ELISA. Twenty-three HBsAg-negative sera with high-concentration RFs were selected randomly to perform dilution with mixed normal sera. Serum models consisting of HBsAg and high-concentration RFs were made by blending high-concentration RFs and HBsAg-positive sera at the ratio of 9:1.

RESULTS

In the 23 samples, one-step ELISA showed that HBsAg-positive rate was 69.57% at dilution of 1:2, 60.87% at dilution of 1:4 and 40.00% at dilution of 1:8, whereas two-step ELISA showed that it was 100% without any dilution. Thirty serum models were made and divided into six groups. Median S/CO value of HBsAg was 3.00 in control, whereas it ranged from 0.13 to 1.78 in the six groups.

CONCLUSIONS

High-concentration RFs cause false decrease of S/CO values of HBsAg using one-step ELISA.

Hepatitis B

Hepatitis B remains a major public health problem around the world. The discovery of the hepatitis C virus has diverted interest from hepatitis B to this new virus and the epidemic associated with it, but hepatitis B remains a significant pathogen for millions of people worldwide. The World Health Organization has suggested that universal vaccination of children against hepatitis B should be implemented in an attempt to reduce the enormous morbidity and mortality associated with infection of this virus group. The review seeks to identify all the newer discoveries relating to hepatitis B that have been made in the past decade. Reference is made to the appearance of hepatitis B mutants which are able to infect patients previously infected with the wild strain of the virus. The implications of mutants on vaccination programmes is raised, as are issues relating to treatment of hepatitis B infection.

Loss of detectable antibody to hepatitis B surface antigen in immunized patients with hemophilia but without human immunodeficiency virus infection

We investigated the loss of detectable antibody directed against the hepatitis B surface antigen after immunization with hepatitis B vaccine in 55 patients who were seronegative for the human immunodeficiency virus and had hemophilia. Twenty percent of patients lost detectable antibody at a mean of 4.6 years after completion of immunization. Monitoring of hepatitis B serostatus or routine revaccination may be necessary.

Clinical laboratory applications of monoclonal antibodies

Monoclonal antibody (MAb) technology is well recognized as a significant development for producing specific serologic reagents to a wide variety of antigens in unlimited amounts. These reagents have provided the means for developing a number of highly specific and reproducible immunological assays for rapid and accurate diagnosis of an extensive list of diseases, including infectious diseases. The impact that MAbs have had in characterizing infectious disease pathogens, as well as their current and future applications for use in clinical microbiology laboratories, is reviewed. In addition, the advantages (and disadvantages) of the use of MAbs in a number of immunoassays, such as particle agglutination, radioimmunoassays, enzyme-linked immunosorbent assays, immunofluorescent-antibody assays, and immunohistology, are explored, including the use of these reagents in novel test system assays. Also, nucleic acid probe technology is compared with the use of MAbs from the perspective of their respective applications in the diagnosis of infectious disease agents. There is no question that hybridoma technology has the potential to alter significantly the methods currently used in most clinical microbiology laboratories.

ELISA: highlights of the present state of the art

ELISA is now very widely used. Many variations on the theme have been described. The search for further improvements is ongoing, mainly in the areas of sensitivity, specificity and practicability. Of course, the application of monoclonal antibodies is important in this respect. Next to that, further improvements in the detection of the enzyme label have come to the fore. Examples regarding the use of tetra-methylbenzidine as a peroxidase-substrate and details on its safety, a novel amplification method for detecting alkaline phosphatase and an enhanced luminescence method to detect peroxidase are given.